2-chloro-8-methylquinoxaline | 61148-40-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-8-methylquinoxaline
• CAS: 61148-40-1
• 化学式: C₉H₇ClN₂
• 分子量: 178.621
• InChiKey: RPRFQQQHIBASPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-8-methylquinoxaline 在 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-methoxy-8-methyl-quinoxaline
  参考文献：
  名称：

  CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES

  摘要：

  该发明涉及公式（I）的抗生素环己基或哌啶基羧酰胺衍生物，其中R1代表氢、卤素、（C1-C4）烷基、（C1-C4）烷氧基、氰基或COOR2，R2为（C1-C4）烷基；U、V、W和X中的一个或两个代表N，其余代表CH，或者在X的情况下，也可以表示为CRX，RX为卤素原子；B表示N，A表示CH2CH2或CH(OR3)CH2，或者B表示CH或C(OR4)，A表示OCH2，CH2CH(OR5)，CH(OR6)CH2，CH(OR7)CH(OR8)，CH═CH或CH2CH2；R3、R4、R5、R6、R7和R8中的每一个独立地代表氢、SO3H、PO3H2、CH2OPO3H2或COR9，R9为CH2CH2COOH或R9-COOH为天然存在的氨基酸或二甲基氨基甘氨酸；以及公式（I）中此类化合物的盐。

  公开号：

  US20090105232A1
• 作为产物：
  描述：

  AR-甲基-AR-硝基苯胺 在 吡啶 、 sodium dithionite 、 五氯化磷 、 sodium hydroxide 、 三氯氧磷 作用下， 以 乙醇 、 水 、 苯 为溶剂， 反应 14.0h， 生成 2-chloro-8-methylquinoxaline
  参考文献：
  名称：

  Design, Synthesis, and Characterization of Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram-Positive Activity

  摘要：

  There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K channel block. On the other hand, analog 49e displayed lower hERG K channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.

  DOI：

  10.1021/jm400963y

文献信息

• [EN] AMINO-SUBSTITUTED ISOTHIAZOLES<br/>[FR] ISOTHIAZOLES AMINO-SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2014118186A1

  公开（公告）日：2014-08-07

  The present invention relates to isothiazoles of general formula (I) which inhibit the mitotic checkpoint : in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）的异噻唑类化合物，其抑制有丝分裂检查点：其中A、R1和R2如权利要求中所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是肿瘤，作为唯一药剂或与其他活性成分组合使用。
• Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines
  作者：Ajit K. Parhi、Yongzheng Zhang、Kurt W. Saionz、Padmanava Pradhan、Malvika Kaul、Kalkal Trivedi、Daniel S. Pilch、Edmond J. LaVoie

  DOI：10.1016/j.bmcl.2013.06.048

  日期：2013.9

  Several phenyl substituted naphthalenes and isoquinolines have been identified as antibacterial agents that inhibit FtsZ-Zing formation. In the present study we evaluated the antibacterial of several phenyl substituted quinoxalines, quinazolines and 1,5-naphthyridines against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and vancomycin-sensitive and vancomycin-resistant Enterococcus

  几种苯基取代的萘和异喹啉已被鉴定为抑制 FtsZ-Zing 形成的抗菌剂。在本研究中，我们评估了几种苯基取代的喹喔啉、喹唑啉和 1,5-萘啶对甲氧西林敏感和耐甲氧西林金 黄色葡萄球菌和万古霉素敏感和耐万古霉素的粪 肠球菌的抗菌作用。一些对金黄色葡萄球菌更有效的化合物评估了它们对 FtsZ 蛋白质聚合的影响。还进行了进一步的研究以评估它们的相对杀菌和抑菌活性。在非季铵化和季铵化喹喔啉衍生物之间观察到的显着差异表明，不同的作用机制与其抗菌特性有关。
• Antimicrobial agents
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US09822108B2

  公开（公告）日：2017-11-21

  The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a substituted bicyclic heteroaromatic ring compound of formula I: wherein two of X1 to X8 are N and the remaining of X1 to X8 are CH; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.

  该发明提供了治疗哺乳动物细菌感染的方法，包括向哺乳动物施用化合物I的取代双环杂芳环化合物：其中X1至X8中的两个是N，其余的X1至X8是CH；或其药用可接受盐，以及公式I的新化合物及其盐和含有公式I化合物或其药用可接受盐的药物组合物。
• [EN] 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3,7-DIAZABICYCLO[3.3.1]NONANE ET DE 9-OXA-3,7- DIAZABICYCLO[3.3.1]NONANE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013050938A1

  公开（公告）日：2013-04-11

  The present invention relates to 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7- diazabicyclo[3.3.1 ]nonane derivatives of formula (I) wherein Ar1 and Ar2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式（I）的3,7-二氮杂双环[3.3.1]壬烷和9-氧-3,7-二氮杂双环[3.3.1]壬烷衍生物，其中Ar1和Ar2如描述中所述，其制备方法，其药学上可接受的盐，以及作为药物的用途，含有一种或多种式（I）化合物的药物组合物，特别是其用作促进睡眠受体拮抗剂。
• New Piperidine Antibiotics
  申请人：HUBSCHWERLEN Christian

  公开号：US20070173532A1

  公开（公告）日：2007-07-26

  The invention relates to novel, antibacterially active piperidine derivatives of the formula wherein one of U and V represents N, the other represents N or CH; M represents CH 2 CH 2 , CH═CH, CH(OH)CH(OH), CH(OH)CH 2 , CH(NH 2 )CH 2 , COCH 2 or OCH 2 ; R 1 represents alkyl, haloalkyl, alkoxy, haloalkoxy, halogen or cyano; R 2 represents hydrogen or halogen; R 3 represents carboxy, carboxamido, alkylaminocarbonyl, hydroxy, aminocarbonyloxy, 2-tetrazolyl or 3-methyl-1,2,4-oxadiazol-5-yl; R 4 represents alkyl, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl, haloalkyl, alkenyl, arylalkyl, aryl-S(O) m -alkyl, heteroarylalkyl, heteroarylaminocarbonylalkyl, heteroaryl-S(O) m -alkyl, CH 2 —CH═CH-aryl or cycloalkyl-S(O) m -alkyl; n is an integer from 0 to 3; and m is 0 or 2.

  该发明涉及一种新的具有抗菌活性的哌啶衍生物，其化学式如下： 其中U和V中的一个代表N，另一个代表N或CH； M代表CH2CH2，CH═CH，CH(OH)CH(OH)，CH(OH)CH2，CH(NH2)CH2，COCH2或OCH2； R1代表烷基，卤代烷基，烷氧基，卤代烷氧基，卤素或氰基； R2代表氢或卤素； R3代表羧基，羧胺基，烷基氨基甲酰基，羟基，氨基甲酰氧基，2-四唑基或3-甲基-1,2,4-噁二唑-5-基； R4代表烷基，(C1-C4)烷氧基-(C1-C4)烷基，卤代烷基，烯基，芳基烷基，芳基-S(O)m-烷基，杂环芳基烷基，杂环芳基氨基甲酰基烷基，杂环芳基-S(O)m-烷基，CH2—CH═CH-芳基或环烷基-S(O)m-烷基；n为0到3的整数；m为0或2。